Compare MMSI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMSI | ACAD |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.8B |
| IPO Year | 1996 | 2000 |
| Metric | MMSI | ACAD |
|---|---|---|
| Price | $67.83 | $21.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $98.88 | $30.55 |
| AVG Volume (30 Days) | 692.0K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.93 | ★ 69.12 |
| EPS | ★ 0.68 | 0.02 |
| Revenue | ★ $1,515,906,000.00 | $726,437,000.00 |
| Revenue This Year | $8.85 | $18.80 |
| Revenue Next Year | $5.88 | $11.70 |
| P/E Ratio | ★ $99.28 | $1,092.00 |
| Revenue Growth | 11.75 | ★ 40.45 |
| 52 Week Low | $59.74 | $19.69 |
| 52 Week High | $96.74 | $28.35 |
| Indicator | MMSI | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 48.91 |
| Support Level | $66.76 | $21.04 |
| Resistance Level | $71.68 | $22.03 |
| Average True Range (ATR) | 1.76 | 0.59 |
| MACD | 0.76 | 0.06 |
| Stochastic Oscillator | 95.64 | 62.82 |
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.